Scinovex
review Open AccessTop 1% cited

Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research

Frontiers in Oncology · 2013 · Vol. 3 · pp. 256–256
Nuzhat AhmedKaye L. Stenvers

Abstract

More than one third of ovarian cancer patients present with ascites at diagnosis, and almost all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread of ovarian cancer and is associated with poor disease prognosis. Malignant ascites acts as a reservoir of a complex mixture of soluble factors and cellular components which provide a pro-inflammatory and tumor-promoting microenvironment for the tumor cells. Subpopulations of these tumor cells exhibit cancer stem-like phenotypes, possess enhanced resistance to therapies and the capacity for distal metastatic spread and recurrent disease. Thus, ascites-derived malignant cells and the ascites microenvironment represent a major source of morbidity and mortality for ovarian cancer patients. This review focuses on recent advances in our understanding of the molecular, cellular, and functional characteristics of the cellular populations within ascites and discusses their contributions to ovarian cancer metastasis, chemoresistance, and recurrence. We highlight in particular recent translational findings which have used primary ascites-derived tumor cells as a tool to understand the pathogenesis of the disease, yielding new insights and targets for therapeutic manipulation.

Ovarian cancer diagnosis and treatmentCytokine Signaling Pathways and InteractionsLymphoma Diagnosis and TreatmentAscitesOvarian cancerTranslational researchMedicineTargeted therapyOncologyCancerInternal medicineCancer researchPathology

Funding

  • State Government of Victoria
Citations
481
FWCI
27.05
field-weighted impact
References
145
Percentile
100%
vs. same field & year
Citations per year
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.